Tivozanib
Tivozanib is a highly selective VEGF-receptor pill for kidney cancer after two or more prior treatments, notable for its tolerability and for a trial that closed the door on immunotherapy rechallenge.
TIVO-3 (2019): PFS 5.6 vs 3.9 months vs sorafenib in third line and beyond; FDA approval March 2021. TiNivo-2 (2024-26): adding nivolumab gave no benefit after prior IO. AVEO, acquired by LG Chem in 2023.
1.Oral dosing 3 weeks on / 1 off
- Route
- Oral
- Schedule
- 1.34 mg daily, 21 days on / 7 days off
- Monitoring
- Blood pressure, thyroid, liver enzymes
- Medicare
- Part D (self-administered)
Oral, self-administered, so it is a Part D drug: covered through a stand-alone Part D plan or Medicare Advantage drug benefit, usually on the specialty tier with 25 to 33% coinsurance until the annual cap ($2,000 in 2025, $2,100 in 2026).
- Commercial insurance
- covered with prior authorisation
Covered for FDA-labelled and NCCN-listed uses, but almost always behind prior authorisation confirming diagnosis, biomarker and line of therapy; dispensed through a specialty pharmacy. Two or more prior systemic therapies for RCC documented.
- Assistance programmes
- PAN Foundation — Disease-specific co-pay and premium funds; open and closed funds change monthly.
- HealthWell Foundation
- CancerCare Co-Payment Assistance Foundation
- Patient Advocate Foundation Co-Pay Relief
Part D out-of-pocket capped at $2,000 (2025) / $2,100 (2026). Medicare patients cannot use manufacturer co-pay cards; charity funds (PAN, HealthWell, CancerCare) and the Extra Help subsidy are the routes.
Sources: Medicare.gov: Drug coverage (Part D) · Medicare.gov: Costs for Medicare drug coverage (annual out-of-pocket cap). Not medical or financial advice; verify with your plan.
- Appraised for
- First-line advanced RCC
- NHS England
- Routinely funded for the appraised indication (or via managed access)
Sources: NICE TA512 · SMC advice: tivozanib. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2021 | Relapsed/refractory advanced RCC after ≥2 prior systemic therapies |
| Adverse event | Any grade | Grade 3+ |
|---|---|---|
| Hypertension | 44% | — |
| Fatigue | 43% | — |
| Diarrhoea | 33% | — |
| Hand-foot syndrome | 15% | — |
Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials in OnCo
Latest papers
topQuery for this drug: (TITLE:"Tivozanib" OR ABSTRACT:"Tivozanib" OR TITLE:"Fotivda" OR ABSTRACT:"Fotivda") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Tivozanib, not a curated reading list.